The House Select Committee on the Chinese Communist Party has drafted the BIOSECURE Act, which aims to prevent U.S. biotechnology companies from collaborating with a Chinese firm that produces critical drug components. The legislation is intended to safeguard U.S. national security by preventing the Chinese government from obtaining access to sensitive American health data. The House Oversight and Accountability Committee will consider the bill next month, hoping to pass it before the July 4th recess and include it in a year-end legislative package.